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Among breast cancers diagnosed at any stage, 20%–30% are found to have HER2 
gene amplification/receptor overexpression that is associated with aggressive 
behaviour (high proliferative activity, metastatic potential and neoangiogenesis) and 
poor outcome. Trastuzumab, the humanized monoclonal antibody against HER2 
receptor, is an essential component of the treatment of patients with HER2-positive 
breast cancer that has change the biological history of the disease. 
In the adjuvant setting, the results of six phase III randomized trials with more than 
10,000 HER2-positive breast cancer patients have been presented so far; different 
chemotherapy regimens and different modalities of trastuzumab administration (in 
combination or sequentially after chemotherapy) have been explored. Five trials have 
demonstrated the superiority of adding trastuzumab to chemotherapy compared with 
chemotherapy alone (the DFS was 33%–52% greater independently from age, nodal 
status, hormonal status, or tumor size and the OS was 34%–41% greater), while only 
PACS04 trial has shown no benefit for adding trastuzumab at the completion of 
chemotherapy versus control. The majority of these trials have tested one year of 
trastuzumab therapy. But the HERA trial is the only one specifically designed to test 
prospectively different durations of trastuzumab administered with sequential 
approach (that is at the end of adjuvant chemotherapy), with positive results in terms 
of DFS and OS; up to now, the results of the comparison of 1 versus 2 years of 
treatment are still not yet available. Moreover, the cytotoxic synergism of combined 
trastuzumab and chemotherapy is supported not only by the previous mentioned 
trials, but also by clinical data in metastatic (25% survival increase) and neoadjuvant 
settings (26.3% of pCR without and 66.7% of pCR with trastuzumab respectively in 
the MDACC experience). Interestingly, a small Finnish study wherein trastuzumab 
was administered for a very short period (9 weekly administrations) concomitantly 
with chemotherapy suggested that a shorter treatment might produce comparable 
efficacy with significant lower toxicities. The cardiac safety of trastuzumab is in fact 
another relevant clinical issue, particularly when it is used as adjuvant therapy. In all 
the adjuvant trastuzumab trials, despite the selection of the optimal patient 
population, symptomatic congestive heart failure occurred in 1.5%-2.5% of the 
patients treated with sequential trastuzumab (HERA trial, PACS 04, and N9831 arm 
B) and in a percentage ranging from 0.4 (BCIRG006 arm C, without anthracyclines) 
to 3.6 of the patients in the trials in which trastuzumab was started concomitantly 
with chemotherapy (BCIRG 006 arm B, N9831 arm C, NSABP B-31); moreover, a 
significant proportion of patients never started trastuzumab because of  LVEF decline 
(1.9-6.4%) or did not complete the planned trastuzumab therapy due to cardiac events 
(6-18%). To test the hypothesis that a shorter duration of adjuvant trastuzumab 
concomitant with chemotherapy might be effective but less toxic, we have designed a 
phase III multicentre, randomized trial in order to evaluate if short (9 weekly 
administrations) versus long (18 three-weekly administrations) adjuvant trastuzumab 
combined with chemotherapy is equally effective in terms of DFS, and less toxic 
from a cardiac viewpoint. Other European trials are addressing the same questions 
(PHARE trial, SOLD trial, PERSEPHONE trial), but in addition this trial will explore 
less intensive adjuvant trastuzumab regimens in the node negative pT1a,b HER2 
positive breast cancer population so poorly represented in most clinical trials.   
At the same time, Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation 
(ALTTO) is a four-arm randomized trial designed to compare adjuvant trastuzumab 
and lapatinib in women with early-stage HER2-positive breast cancer: it examine 
which anti-HER2 agent is more effective and which is the best schedule of 
administration, namely, what benefit will be derived by taking the drugs separately, 
in tandem order or in combination. Moreover, the TEACH trial is designed to 
determine whether adjuvant therapy with lapatinib for 1 year will improve DFS. 
Finally, the strategy for using adjuvant trastuzumab monotherapy with or without 
endocrine therapy, for tumors judged to be low risk by routine clinico-pathological or 
molecular assessment is till controversial. 
In summary, many questions related to trastuzumab use in the adjuvant setting still 
remain unanswered, regarding to the optimum timing and duration of treatment, its 
role in small node-negative tumors, the optimum therapy regimens. 
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